Clin Psychopharmacol Neurosci.
2022 Aug;20(3):581-583. 10.9758/cpn.2022.20.3.581.
Aripiprazole Improved Post-Streptococcal Dyskinesia by Modulating Dopaminergic Activity: A Case Report
- Affiliations
-
- 1Department of Psychiatry, Chung-Ang University College of Medicine, Seoul, Korea
- 2Department of Nuclear Medicine, Chung-Ang University Hospital, Seoul, Korea
- KMID: 2532829
- DOI: http://doi.org/10.9758/cpn.2022.20.3.581
Abstract
- This case report aimed to discuss the efficacy of aripiprazole for dyskinesia in patients with functional movement disorder after streptococcal infection, with its biological action of modulating dopamine hyperactivity in the basal ganglia as a dopamine partial agonist. This report has shown that the [18F] N ‐(3‐Fluoropropyl)‐2β‐carbon ethoxy‐3β‐(4‐iodophenyl) nortropane positron emission tomography findings of the patient revealed that the dopamine hyperactivity in the basal ganglia at baseline was normalized after aripiprazole treatment due to its balancing effect as a dopamine partial agonist.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Aripiprazole Induced Tardive Dyskinesia in a Neuroleptic-Naive Patient with Two Years of Follow Up
- Tardive Dyskinesia: Treatment with Aripiprazole
- First Manic Episode in a Young Woman with Schizophrenia after Initiation of Oral Aripiprazole and Aripiprazole Long-Acting Injection
- Clinical Usefulness of Aripiprazole Treatment in a Girl with Prader-Willi Syndrome and Psychosis
- Worsening of Psychotic Symptoms in Patients with Chronic Schizophrenia after Switching to or Combining Aripiprazole and Aripiprazole Monthly (Abilify Maintena)
